Tongxinluo Reduced Of C-Reactive Protein In Patients With Acute Coronary Syndrome Infarction:A Meta Analysis

Objective:To investigate the treatment efficacy of C–reactive protein and high-sensitivity C–reactive protein between western medicine combined Tongxinluo capsule and western medicine in patients with acute coronary syndrome.Methods:We systematic and exhaustive retrieved the Chinese and foreign language databases from their establishment date to December of 2015 to collect the randomized, controlled and clinical trials about the treatment efficacy of C–reactive protein and high-sensitivity C–reactive protein between western medicine combined Tongxinluo capsule and western medicine in patients with acute coronary syndrome, and then the RevMan5.2 soft ware was used for Meta analyses.Results:A total of 28 randomized controlled trials were included, involving 1949 patients and mean duration of 8.7±9.2 weeks. The results of Meta analyses showed that Compared with the control group, The same is that Tongxinluo apsule combined with western medicine had more advantages in reducing high-sensitivity C–reactive protein for the patients with acute coronary syndrome [MD=-2.77,95%CI(-3.47-2.07);P<0.00001];The advantage for this type of patients in reducing the High-sensitivity Creactive protein was the same [MD=-2.12,95%CI(-2.75,-1.49);P<0.00001].Conclusion: In this study, in the treatment of the patients with acute coronary syndrome, Tongxinluo combined western medicine could obviously reduce the inflammatory reaction than single using western medicine.